Dr. Reddy's Laboratories Limited RDY PHARMA
Company Overview
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Why Investors Should Care
Revenue has grown at a 11.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Mar 2026 Revenue of $335.93B (+3.2% YoY); net profit $42.85B.
- Trailing 12 Months Year-on-year growth — revenue -5.6%, earnings -68.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR -1.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.96% |
| 1 Year: | -5.60% |
Compounded Profit Growth
| 5 Years: | -1.67% |
| 1 Year: | -68.70% |
Stock Price Performance
| 1 Year: | -16.10% |
| 6 Months: | -16.86% |
| 3 Months: | -9.57% |
| 1 Month: | -2.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.18 · Neutral
P/E of 28.98 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.0% over 5 years.
CONS
- Earnings shrank at -1.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RDY Dr. Reddy's Laboratories Limited PHARMA | 11.88 | 28.98 | $9.90B | 0.68% | 12.17% | 8.84% | 10.96% | -1.67% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 85.45B | 88.05B | 87.27B | 75.16B | 80.70B |
| Cost of Revenue | - | 36.83B | 39.91B | 40.46B | 32.13B | 43.16B |
| Gross Profit | - | 48.63B | 48.14B | 46.81B | 43.03B | 37.54B |
| Operating Expenses | - | 31.79B | 30.27B | 32.48B | 42.21B | 34.51B |
| Operating Income | - | 16.84B | 17.87B | 14.33B | 829.00M | 3.03B |
| EBITDA | - | 24.64B | 24.31B | 21.59B | 8.63B | 12.15B |
| Interest Expense | - | 830.00M | 907.00M | 944.00M | 1.06B | 1.25B |
| Pretax Income | - | 19.05B | 18.35B | 15.43B | 2.00B | 5.53B |
| Tax Provision | - | 4.95B | 4.08B | 3.53B | -216.00M | 1.18B |
| Net Income | - | 14.18B | 14.37B | 12.10B | 2.21B | 4.43B |
| Diluted EPS | - | 17.02 | 17.25 | 14.52 | 2.65 | 5.32 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 245.88B | 279.16B | 325.54B | 335.93B |
| Cost of Revenue | - | 106.54B | 115.56B | 135.11B | 158.67B |
| Gross Profit | - | 139.34B | 163.61B | 190.43B | 177.26B |
| Operating Expenses | - | 80.29B | 98.30B | 118.41B | 127.14B |
| Operating Income | - | 59.05B | 65.31B | 72.01B | 50.12B |
| EBITDA | - | 74.43B | 88.42B | 96.67B | 79.16B |
| Interest Expense | - | 1.43B | 1.71B | 2.83B | 3.74B |
| Pretax Income | - | 60.37B | 71.87B | 76.78B | 54.82B |
| Tax Provision | - | 15.30B | 16.19B | 19.54B | 12.35B |
| Net Income | - | 45.07B | 55.68B | 56.54B | 42.85B |
| Diluted EPS | - | 54.17 | 66.92 | 67.78 | 51.42 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 321.85B | 387.52B | 492.99B | 579.35B |
| Current Assets | - | 204.25B | 248.05B | 250.11B | 301.98B |
| Cash & Equivalents | - | 5.78B | 7.11B | 14.65B | 15.37B |
| Inventory | - | 48.67B | 63.55B | 71.08B | 76.53B |
| Receivables | - | 72.48B | 80.30B | 90.42B | 101.22B |
| Total Liabilities | - | 90.86B | 106.97B | 155.82B | 198.89B |
| Current Liabilities | - | 85.84B | 96.04B | 130.39B | 167.57B |
| Long Term Debt | 3.80B | - | 3.80B | 3.80B | 12.20B |
| Total Debt | - | 13.47B | 20.02B | 46.77B | 77.34B |
| Total Equity | - | 230.99B | 280.55B | 333.39B | 377.06B |
| Shares Outstanding | - | 832.64M | 834.09M | 834.46M | 834.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 58.88B | 45.43B | 46.43B | 56.76B |
| Investing Cash Flow | - | -41.37B | -40.28B | -58.08B | -65.51B |
| Financing Cash Flow | - | -26.86B | -3.76B | 18.91B | 8.29B |
| Capital Expenditure | - | -18.87B | -27.43B | -34.40B | -38.42B |
| Free Cash Flow | - | 40.01B | 18.00B | 12.03B | 18.33B |
| Net Change in Cash | - | -9.36B | 1.39B | 7.26B | -468.00M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.7% | 58.6% | 58.5% | 52.8% |
| Operating Margin % | - | 24.0% | 23.4% | 22.1% | 14.9% |
| Net Margin % | - | 18.3% | 19.9% | 17.4% | 12.8% |
| ROE % | - | 19.5% | 19.8% | 17.0% | 11.4% |
| ROCE % | - | 25.0% | 22.4% | 19.9% | 12.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Robeco Institutional Asset Management B.V. | 2.16% | 18.02M | $219.68M |
| 2 | Morgan Stanley | 1.31% | 10.94M | $133.31M |
| 3 | Blackrock Inc. | 1.27% | 10.59M | $129.04M |
| 4 | Royal Bank of Canada | 1.10% | 9.21M | $112.31M |
| 5 | Aikya Investment Management Ltd | 1.02% | 8.49M | $103.54M |
| 6 | Renaissance Technologies, LLC | 0.88% | 7.35M | $89.56M |
| 7 | Dimensional Fund Advisors LP | 0.64% | 5.31M | $64.75M |
| 8 | State Street Corporation | 0.49% | 4.12M | $50.28M |
| 9 | JPMORGAN CHASE & CO | 0.49% | 4.07M | $49.61M |
| 10 | Alliancebernstein L.P. | 0.45% | 3.73M | $45.48M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RDY
Nykredit A S Takes $2 Million Position in Dr. Reddy's Laboratories Ltd $RDY - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQa1lMdHA0YzRweEV4SVJDbEtpUzNoVnRmT2FCRGwtVUJNWGtrenBfbmtkcVlqUmltSEZCcVBrb0Z2bzZJQ2xtY19FVVZWQkU4RGFING10dDlIUEMzb3dMMTlaUHR3NjRXc3RyN0ktSDBpUjF0d3dsenJWM29Ic2NFemJ2VndHSmxDR3p4MG…
Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis: Evaluating A 13.17% Potential Upside Amid Market Challenges - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQbUlMSlFYdjdZVnRqMG8yQkk3d2w5SFJlVi1XQlE1cFZ2dkoxQkpCb3RaazNIYzIxOGx1UlFoSkRKYXpGVU5Sd3VPMjVyb2xRWVI0Z3pQV0I4aFMtN2JwMm5rNjVYSzY3QVRRVi16Yjl2cmUya0U4LXh5SGhqSV9LbU9ZbXp0eXl5RjFYc3…
Dr. Reddy's Laboratories (RDY) Stock Falls on Q4 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdmQxZEc4eF9SLTJBZW56Ul9OSDBtb1RVRU5ZWHFZMldxZ0tDYW50dE80NVBZdHBRYTRMbHM4cE51WnJfZkpxSEcxc0Y4cS1NTDk3TERTcEtZeTI1bE9ZejZVbGJNQlVsY2tvZXcwNUNHR2owbV9rQmJxeHItYXE1eV96OXJ2T1BjT2xQeE…
Trading Systems Reacting to (RDY) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQTGtvY1I2bzE4Z0JtMXZzdHlwMWdNMzhEaVZJSU9xOUhhdzE5RU5POXNsb0U5ZTNONllsRFljOWpTcmJqd3dsWDRwVUtQZmxreWFPUi0wRk03YTVkNHNWQ0RyZXVlb1hydGFydjlyaXg4OVNqTnpPOXM4VlhQWl9zczhjbWZoSVRDRDAzX2…
Dr. Reddy’s Laboratories (NYSE: RDY) approves 15,933 ESOP grant at Rs. 1,206 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPMUNubVYwSVFqRzlYNVRzUzYwZ3prTnpxQ2JUSmNiclJoZVI5WVFZUHBaQmRoVDdMYXZwaFRjS2lhb1lCTVRfUWk3VzIzSEQ4UmlJazI1Sy00SWhkeTJkTXFrYmNIdmJzelRacm9oYWJ2LWtwVFg5d3g3UDNseTU2OWxYUGhKODNfTkpROW…
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQU2ZDdUdEMjdHMkJYLTlvcUdsOEM2SnFBSkhhXzBZLVIteG9xNW14c0VtNzZCTEdObUpPQV8tZUNQdFEyQWQzLTl2bXZ1eXNKZFdBZlhOUk9kc00xN0ljWm5jNHZwb1pZbGJjUjFlSkNZcWFjOVZLeklkOGFXbENRNzR5ZkY0RVVZRXgxY1…
RDY — Frequently Asked Questions
What is the current share price of Dr. Reddy's Laboratories Limited (RDY)?
As of 2026-09-19 21:16 PDT, Dr. Reddy's Laboratories Limited (RDY) trades at $11.88 on NYSE. Its 52-week range is $11.30 to $15.27.
What is the market capitalisation of RDY?
Dr. Reddy's Laboratories Limited (RDY) has a market capitalisation of $9.90B on NYSE.
What is the P/E ratio of RDY?
RDY trades at a trailing price-to-earnings (P/E) ratio of 28.98. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 15.20.
Does RDY pay a dividend?
Dr. Reddy's Laboratories Limited (RDY) currently offers a dividend yield of 0.68%.
What is the return on equity (ROE) of RDY?
RDY has a return on equity (ROE) of 8.84%. Its return on capital employed (ROCE) is 12.17%.
Is RDY a good stock to buy?
This page provides a data-driven analysis of Dr. Reddy's Laboratories Limited (RDY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.